SCHEMBL12434759

SCHEMBL12434759

COc1cc(F)c(-c2ccccc2C)cc1OBO

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ S1PR1 P21453 3/20 0.37
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ IDO1 P14902 1/20 0.35
▸ PDE2A O00408 1/20 0.35
▸ PDE10A Q9Y233 1/20 0.35
▸ TUBB1 Q9H4B7 2/20 0.34
▸ KIT P10721 1/20 0.34
▸ TUBB4A P04350 1/20 0.34
▸ TUBB P07437 1/20 0.34
▸ TUBA3C P0DPH7 1/20 0.34
▸ TUBA1B P68363 1/20 0.34
▸ TUBA4A P68366 1/20 0.34
▸ TUBB4B P68371 1/20 0.34
▸ TUBB3 Q13509 1/20 0.34
▸ TUBB2A Q13885 1/20 0.34
▸ TUBB8 Q3ZCM7 1/20 0.34
▸ TUBA3E Q6PEY2 1/20 0.34
▸ TUBA1A Q71U36 1/20 0.34
▸ TUBA1C Q9BQE3 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19077653 0.77 SMN1; SMN2 (0.41) IDO1TUBB1TUBB4ATUBBTUBA3C
SCHEMBL12767822 0.77 ENPP2 (0.43) S1PR1PDE2APDE10ATUBB1TUBB4A
SCHEMBL17752371 0.76 PDGFRB (0.46) TUBB1KITTUBB4ATUBBTUBA3C
SCHEMBL1529047 0.76 S1PR1 (0.40) S1PR1MEN1KMT2APDE2APDE10A
SCHEMBL16303551 0.75 FPR2 (0.36) KITERN1FPR2SCN9A
SCHEMBL17752376 0.74 FPR2 (0.44) PDE10AFPR2SCN9ATSHR
SCHEMBL17752330 0.70 HTR2A (0.40) MEN1KMT2ARAB9AHTR2CKDM4E
SCHEMBL15031956 0.70 HTR2A (0.40) MEN1KMT2ARAB9AHTR2CKDM4E
SCHEMBL17752326 0.70 LCK (0.41) ERN1HTR2CALDH1A1
SCHEMBL22819957 0.69 ACHE (0.48) ALOX5APFEN1RAB9AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8440702-B2 1,3-oxazolidin -2-one derivatives useful as CETP inhibitors MERCK SHARP & DOHME CORP. (US) 2013-05-14 — — US disclosed
US-20110178059-A1 1,3-OXAZOLIDIN -2-ONE DERIVATIVES USEFUL AS CETP INHIBITORS MERCK SHARP & DOHME CORP. (US) 2011-07-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178059-A1 1,3-OXAZOLIDIN -2-ONE DERIVATIVES USEFUL AS CETP INHIBITORS CETP, MTTP, APOB S1PR1 1601/4885MEN1 4049/4885KMT2A 2516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback